These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35608040)

  • 1. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
    Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
    Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
    Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
    ESC Heart Fail; 2020 Dec; 7(6):3942-3949. PubMed ID: 32924285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.
    Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar AD; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD
    Heart; 2022 Mar; 108(6):474-478. PubMed ID: 33990410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
    Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
    J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
    Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
    Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL; Maurer MS
    JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis.
    Ioannou A; Nitsche C; Porcari A; Patel RK; Razvi Y; Rauf MU; Martinez-Naharro A; Venneri L; Accietto A; Netti L; Bandera F; Virsinskaite R; Kotecha T; Knight D; Petrie A; Whelan C; Wechalekar A; Lachmann H; Hawkins PN; Gillmore JD; Fontana M
    J Am Heart Assoc; 2024 Feb; 13(4):e033094. PubMed ID: 38314569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
    Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
    JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.
    Takashio S; Tokitsu T; Matsukawa M; Sakaino N; Fujimoto K; Sakamoto T; Noda K; Tsunoda R; Misumi I; Hirai N; Doi H; Koide S; Mizuno Y; Hirose T; Kurokawa H; Kajiwara I; Ohba K; Miyamoto S; Araki S; Yamamoto E; Matsushita K; Ueda M; Tsujita K;
    J Cardiol; 2022 Jul; 80(1):49-55. PubMed ID: 35078683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
    Nagano N; Muranaka A; Nishikawa R; Ohwada W; Kouzu H; Kamiyama N; Fujito T; Mochizuki A; Nagahara D; Nakanishi M; Ohkubo Y; Hisahara S; Nakao S; Katoh N; Ishikawa A; Sakurai A; Yano T
    Int Heart J; 2022; 63(1):168-175. PubMed ID: 35095067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.